Suppr超能文献

应用 Nevelia 皮肤-表皮再生模板治疗缺血性糖尿病足术后创面。

Use of Nevelia Dermal-Epidermal Regenerative Template in the Management of Ischemic Diabetic Foot Postsurgical Wounds.

机构信息

University of Tor Vergata, Rome, Italy.

出版信息

Int J Low Extrem Wounds. 2020 Sep;19(3):282-288. doi: 10.1177/1534734619896460. Epub 2020 Jan 29.

Abstract

The purpose of this cross-sectional study is evaluate the effectiveness of a dermal-epidermal substitute (DES) composed of 3-dimensional porous matrix of type 1, purified, stabilized, bovin-origin collagen (Nevelia, SYMATESE, Chaponost, France) without a subsequent skin graft in the treatment ischemic postsurgical diabetic foot ulcers. This study group was composed of a sample of consecutive diabetic patients with critical limb ischemia and postsurgical wounds. All patients received a preset limb salvage protocol including the application of the DES, but none received a skin graft. Patients were closely followed until wound healing or different outcome. The outcome measures were healing, nonhealing, major amputation, and death evaluated at 1 and 2 years of follow-up. Forty-one patients were included. The average postsurgical wound area was 69.6 ± 50 cm. Twenty-one patients (51%) healed; 10 patients (24%) did not heal after 1 year of follow-up; however, all of them achieved a mean ulcer size reduction >50%; 7 patients (17%) were amputees; 3 patients (7.3%) died. In a later follow-up (2 years), wounds in 8 additional patients healed. Successful revascularization was an independent predictor of healing (hazard ratio = 5.1, 95% confidence interval [CI] = 2.5-14-9; = .0001), the postsurgical ulcer size (>50 cm) was an independent predictor of nonhealing (hazard ratio = 6.2, 95% CI = 2.1-38.4; = .0001) while recurrence of critical limb ischemia was an independent predictor of major amputation (odds ratio = 3.4, 95% CI = 1.1-4.5; = .002). The DES composed of type 1 bovin-origin collagen is useful in the treatment of large postsurgical diabetic foot ulcers, even when the skin graft is not a suitable therapeutic option.

摘要

本横断面研究旨在评估一种由 1 型、纯化、稳定的牛源胶原蛋白(Nevelia,SYMATESE,Chaponost,法国)组成的真皮-表皮替代物(DES)的有效性,该替代物无随后的皮肤移植,用于治疗缺血性糖尿病术后足部溃疡。该研究组由一组连续的患有严重肢体缺血和术后伤口的糖尿病患者组成。所有患者均接受了预设的肢体保全方案,包括应用 DES,但均未进行皮肤移植。密切随访患者直至伤口愈合或出现不同的结果。主要终点是 1 年和 2 年随访时的愈合、未愈合、大截肢和死亡。共纳入 41 例患者。平均术后伤口面积为 69.6 ± 50 cm。21 例(51%)患者愈合;10 例(24%)患者在 1 年随访后未愈合,但所有患者的溃疡面积均减少>50%;7 例(17%)患者截肢;3 例(7.3%)患者死亡。在后续随访(2 年)中,另外 8 例患者的伤口愈合。成功的再血管化是愈合的独立预测因素(风险比=5.1,95%置信区间[CI]为 2.5-14-9;=.0001),术后溃疡面积(>50 cm)是未愈合的独立预测因素(风险比=6.2,95%CI=2.1-38.4;=.0001),而严重肢体缺血的复发是大截肢的独立预测因素(比值比=3.4,95%CI=1.1-4.5;=.002)。由 1 型牛源胶原蛋白组成的 DES 可有效治疗大型糖尿病术后足部溃疡,即使皮肤移植不是合适的治疗选择。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验